Fellow Health Joins Progyny Network for Home Male Fertility Testing
Partnership provides mail-in semen analysis as a covered benefit for eligible members.
Partnership provides mail-in semen analysis as a covered benefit for eligible members.
The vaginal microbiome is a complex and dynamic ecosystem that varies across populations; research is limited by geographical disparities.
NIH researchers found undetected cancers in nearly half of pregnant people with abnormal prenatal cfDNA test results.
A study found that elevated blood levels of LDL cholesterol, Lp(a), and CRP significantly increase long-term cardiovascular risk.
Read MoreEndometriosis affects over 11% of women and remains challenging to diagnose early, with researchers exploring new diagnostic methods.
Read MoreResearchers are using advanced AI technology, EpiSign, to diagnose rare genetic diseases and prenatal exposure-related birth abnormalities.
Read MoreGattaca Genomics aims to enhance family-building through advanced prenatal genetic screening, increasing the success rates and access.
Read MoreA new home-based questionnaire can identify individuals at high risk of heart attacks with the same accuracy as clinical blood tests.
Read MoreMenarini Silicon Biosystems presented a study, about its advanced non-invasive prenatal testing technology using maternal blood.
Read MoreMeasuring blood levels of homocysteine can help predict the risk and progression of obstructive sleep apnea.
Read MoreRecent advancements in congenital CMV (cCMV) screening underscore the need for enhanced awareness and legislative action.
Read MoreThe test monitors pregnant women for Toxoplasma gondii infections, and detects infections within 30 minutes from a finger-prick.
Read MoreLabs should consider self-reported race when screening for open neural tube defects to improve prenatal care equity for Black individuals.
Read MoreLabcorp has introduced a first trimester preeclampsia screening test to assess preeclampsia risk between 11- and 14-weeks’ gestation.
Read MorePinkDx, an early-stage company focused on positively impacting the health of women, launched with $40 million in Series A financing.Â
Read MoreResearchers in the U.S. and the Netherlands have now used a large dataset to build more accurate cardiovascular risk models.
Read MoreClinicians can now use two new biomarker-based assays in combination to determine which patients are at higher risk for poor outcomes.
Read MoreAgilent Technologies announced that its GenetiSure Dx Postnatal Assay received European IVDR Class C Certification.
Read More